MRS 2395 is primarily utilized in research settings to study the role of purinergic receptors, particularly the P2Y12 receptor, in various physiological and pathological processes. It serves as a selective antagonist for P2Y12, making it a valuable tool in investigating platelet aggregation and thrombosis. Researchers use it to explore its potential in modulating inflammatory responses and its implications in cardiovascular diseases. Additionally, MRS 2395 is employed in neurological studies to understand its effects on neuroinflammation and its potential therapeutic applications in conditions like stroke or neurodegenerative disorders. Its specificity allows for targeted studies on receptor signaling pathways and their broader biological impacts.